Bonraybio Co., Ltd. (TPE:6955)

Taiwan · Delayed Price · Currency is TWD

89.00

-1.00 (-1.11%)

Oct 30, 2026, 1:30 PM CST

Market Cap	2.70B -35.9%
Revenue (ttm)	332.21M +22.6%
Net Income	107.98M +27.8%
EPS	3.54 +37.0%
Shares Out	30.38M
PE Ratio	25.12
Forward PE	n/a
Dividend	1.22 (1.38%)
Ex-Dividend Date	Mar 19, 2026

Volume	15,006
Open	88.30
Previous Close	90.00
Day's Range	87.30 - 89.00
52-Week Range	87.30 - 144.49
Beta	0.13
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 11, 2026

About Bonraybio

Bonraybio Co., Ltd., a development stage company, manufactures medical instruments and solutions for the male infertility market. The company provides LensHooke X12 PRO semen analysis systems; and LensHooke X1 PRO semen quality analyzers. It also provides consumables, such as CS3 semen test slides; CA0/CA1 sperm separation solutions; and CS1 semen test cassettes. In addition, the company provides X QC Reticles, X QC video tools, and X QC beads; sperm DNA fragmentation test kits; and S10 data consolidation software. Bonraybio Co., Ltd. was found... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2015

Country Taiwan

Stock Exchange Taiwan Stock Exchange

Ticker Symbol 6955

Full Company Profile

Financial Performance

In 2025, Bonraybio's revenue was 306.31 million, an increase of 37.43% compared to the previous year's 222.88 million. Earnings were 102.51 million, an increase of 49.94%.

Financial Statements